Work

Supplementary Table S5 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Table S5. Statistical comparisons of effector and suppressor immune cell populations in patients with de novo resistance (DR) and acquired resistance (AR) to anti-PD1 therapy.

DOI: 10.1158/1078-0432.28332793

Authors: Faye M. Johnson, Madison P. O’Hara, Lacin Yapindi, Peixin Jiang, Hai T. Tran, Alexandre Reuben, Weihong Xiao, Maura L. Gillison, Xiaowen Sun, Alexander Khalaf, J. Jack Lee, Jagannadha K. Sastry, Soma Ghosh

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4407109920

Cites:

Cited by:

Related to: 10